UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
Key PointsUBS sees approximately 250% upside potential for Viking shares over the next year.
Key PointsUBS sees approximately 250% upside potential for Viking shares over the next year.